| Active substance |
Letrozole |
| Also known as |
Letrozole |
| Blood pressure |
May cause a decrease |
| Chemical name |
Letrozole |
| Dosage (medical) |
2.5 mg once daily |
| Dosage (sports) |
1.25 mg to 2.5 mg every other day |
| Effects |
Reduces estrogen levels, increases luteinizing hormone (LH) and follicle-stimulating hormone (FSH) |
| Formula |
C17H11N5 |
| Half-life |
Approximately 2 days |
| Hepatotoxicity |
Low |
| Lab Test |
Monitoring of blood estrogen levels and liver function tests |
| Main action |
Inhibits the enzyme aromatase, which is involved in estrogen synthesis |
| Side effects |
Hot flashes, joint pain, fatigue, risk of osteoporosis |
| Storage conditions |
Store at room temperature away from moisture and heat |
| Substance class |
Aromatase inhibitor |
| Trade name |
Femara |
| Use in sports |
Used to counteract the side effects of estrogen produced by aromatizing anabolic steroids |
| Water Retention |
None |
| Manufacturer |
Novarttis |
| Packing |
30tabs (2,5mg/tab) |
